CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: APOL1 (ImmuneEditome ID:8542)

1. Gene summary of enriched editing regions for APOL1

check button Gene summary
Gene informationGene symbol

APOL1

Gene ID

8542

GeneSynonymsAPO-L|APOL|APOL-I|FSGS4
GeneCytomap

22q12.3

GeneTypeprotein-coding
GeneDescriptionapolipoprotein L1|apolipoprotein L 1|apolipoprotein L1-B3
GeneModificationdate20230521
UniprotIDO14791;B1AH95
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr22:36266068-36266899:+ENST00000397279.7ENSG00000100342.19APOL1splicingAluSc,AluYchr22:36266068-36266899:+.alignment


Top

2. Tumor-specific enriched editing regions for APOL1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr22:36266068-36266899:+BRCAEER1.5446e-11image
ENSG00000100342.19,APOL1BRCAEAG1.5446e-11image
chr22:36266068-36266899:+COADEER2.3371e-11image
ENSG00000100342.19,APOL1COADEAG2.3371e-11image
chr22:36266068-36266899:+HNSCEER1.8912e-12image
ENSG00000100342.19,APOL1HNSCEAG1.8912e-12image
chr22:36266068-36266899:+KICHEER3.7550e-02image
ENSG00000100342.19,APOL1KICHEAG3.7550e-02image
chr22:36266068-36266899:+KIRCEER3.2537e-02image
ENSG00000100342.19,APOL1KIRCEAG3.2587e-02image
chr22:36266068-36266899:+KIRPEER4.9717e-02image
ENSG00000100342.19,APOL1KIRPEAG4.9717e-02image
chr22:36266068-36266899:+LUADEER8.9043e-07image
ENSG00000100342.19,APOL1LUADEAG8.9043e-07image
chr22:36266068-36266899:+LUSCEER1.5459e-05image
ENSG00000100342.19,APOL1LUSCEAG1.5459e-05image
chr22:36266068-36266899:+PRADEER4.0486e-04image
ENSG00000100342.19,APOL1PRADEAG4.1568e-04image
chr22:36266068-36266899:+UCECEER8.8823e-09image
ENSG00000100342.19,APOL1UCECEAG8.8823e-09image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr22:36266068-36266899:+BRCAPathEER1.3874e-044.8201e-020.0606image
ENSG00000100342.19,APOL1BRCAPathEAG1.3874e-044.8201e-020.0606image
ENSG00000100342.19,APOL1KIRCPathEAG5.2112e-068.2105e-070.2116image
chr22:36266068-36266899:+KIRCPathEER5.2332e-068.2391e-070.2116image
ENSG00000100342.19,APOL1KIRPCliEAG3.1151e-033.8597e-040.2504image
chr22:36266068-36266899:+KIRPCliEER3.1151e-033.8597e-040.2504image
ENSG00000100342.19,APOL1LUSCPathEAG3.7693e-021.4613e-020.1096image
chr22:36266068-36266899:+LUSCPathEER3.7693e-021.4613e-020.1096image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr22:36266068-36266899:+LUADEER5.7885e-034.8265e-031.0775e+02image
ENSG00000100342.19,APOL1LUADEAG5.7885e-034.8265e-031.0775e+02image

Top

3. Enriched editing regions and immune related genes for APOL1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr22:36266068-36266899:+BLCAEERENSG00000019102,VSIG2-0.46747.7916e-202.0824e-21-0.4482imageNEIF4A3;NOP58;TAF15VSIG2T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr22:36266068-36266899:+BLCAEERENSG00000263465,SRSF8-0.44644.1665e-187.6207e-21-0.4425imageNEIF4A3;ELAVL1;HNRNPC;NOP58;TAF15;TARDBP;U2AF2NAMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr22:36266068-36266899:+BLCAEERENSG00000137642,SORL1-0.44327.3685e-182.7951e-18-0.4149imageNEIF4A3;ELAVL1;HNRNPC;NOP58;TAF15;TARDBP;U2AF2SORL1T_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr22:36266068-36266899:+BLCAEERENSG00000064787,BCAS1-0.43705.5631e-171.3052e-17-0.4072imageNEIF4A3;ELAVL1;TAF15;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr22:36266068-36266899:+BLCAEERENSG00000086696,HSD17B2-0.41201.3178e-154.3837e-19-0.4238imageNEIF4A3;ELAVL1;HNRNPC;TAF15;TARDBP;U2AF2NAT_cells_CD4_naiveGSVA_HALLMARK_SPERMATOGENESIS
chr22:36266068-36266899:+BLCAEERENSG00000130309,COLGALT10.41212.4791e-152.8316e-170.4033imageNEIF4A3;ELAVL1;HNRNPC;NOP58;TAF15;TARDBP;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr22:36266068-36266899:+BLCAEERENSG00000012779,ALOX5-0.40381.5418e-141.0529e-17-0.4083imageNEIF4A3;ELAVL1;NOP58;TAF15;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr22:36266068-36266899:+BLCAEERENSG00000261338,RP11-378A13.1-0.39803.7543e-146.3028e-19-0.4221imageNELAVL1;HNRNPC;TAF15;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_SPERMATOGENESIS
chr22:36266068-36266899:+BLCAEERENSG00000172830,SSH3-0.39683.7843e-141.2056e-17-0.4076imageNEIF4A3;HNRNPC;NOP58;TAF15;TARDBP;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_SPERMATOGENESIS
chr22:36266068-36266899:+BLCAEERENSG00000164430,MB21D10.38734.9161e-131.4483e-170.4067imageNEIF4A3;ELAVL1;HNRNPC;NOP58;TAF15;U2AF2MB21D1T_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for APOL1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr22:36266068-36266899:+
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.48727.7294e-205.1178e-25-0.4831imageNEIF4A3;ELAVL1;HNRNPC;NOP58;TAF15;TARDBP;U2AF2PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000100342.19,APOL1
BLCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.48728.6826e-205.1178e-25-0.4831imageNADAR;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28B;LSM11;MSI2;NONO;NOP58;PCBP2;PRPF8;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAGPRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for APOL1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr22:36266068-36266899:+ACCEERT_cells_CD4_naive3.3056e-020.2668image
ENSG00000100342.19,APOL1ACCEAGT_cells_CD4_naive3.3056e-020.2668image
chr22:36266068-36266899:+BLCAEERMacrophages_M15.1243e-140.3624image
ENSG00000100342.19,APOL1BLCAEAGMacrophages_M15.1244e-140.3624image
chr22:36266068-36266899:+BRCAEERB_cells_naive3.2550e-10-0.1908image
ENSG00000100342.19,APOL1BRCAEAGB_cells_naive3.2550e-10-0.1908image
chr22:36266068-36266899:+CESCEERMacrophages_M11.5386e-040.2161image
ENSG00000100342.19,APOL1CESCEAGMacrophages_M11.5386e-040.2161image
chr22:36266068-36266899:+COADEERMacrophages_M12.1551e-040.2242image
ENSG00000100342.19,APOL1COADEAGMacrophages_M12.1551e-040.2242image
chr22:36266068-36266899:+DLBCEERMacrophages_M16.6647e-040.4740image
ENSG00000100342.19,APOL1DLBCEAGMacrophages_M16.6647e-040.4740image
chr22:36266068-36266899:+ESCAEERT_cells_regulatory_(Tregs)9.6439e-03-0.2041image
ENSG00000100342.19,APOL1ESCAEAGT_cells_regulatory_(Tregs)9.6532e-03-0.2040image
chr22:36266068-36266899:+HNSCEERMacrophages_M12.1016e-100.2797image
ENSG00000100342.19,APOL1HNSCEAGMacrophages_M12.1016e-100.2797image
chr22:36266068-36266899:+KIRCEERMast_cells_resting1.2318e-04-0.1945image
ENSG00000100342.19,APOL1KIRCEAGMast_cells_resting1.2259e-04-0.1945image
chr22:36266068-36266899:+KIRPEERMacrophages_M12.6628e-060.2745image
ENSG00000100342.19,APOL1KIRPEAGMacrophages_M12.6628e-060.2745image
ENSG00000100342.19,APOL1LAMLEAGT_cells_CD81.0286e-020.4114image
chr22:36266068-36266899:+LIHCEERMacrophages_M14.7827e-030.1458image
ENSG00000100342.19,APOL1LIHCEAGMacrophages_M14.4926e-030.1468image
chr22:36266068-36266899:+LUADEERT_cells_CD4_memory_activated2.8286e-050.1848image
ENSG00000100342.19,APOL1LUADEAGT_cells_CD4_memory_activated2.8286e-050.1848image
chr22:36266068-36266899:+LUSCEERMacrophages_M13.3324e-070.2265image
ENSG00000100342.19,APOL1LUSCEAGMacrophages_M13.3324e-070.2265image
chr22:36266068-36266899:+MESOEERMacrophages_M18.5436e-040.3613image
ENSG00000100342.19,APOL1MESOEAGMacrophages_M18.5436e-040.3613image
chr22:36266068-36266899:+OVEERT_cells_follicular_helper4.5347e-050.2383image
ENSG00000100342.19,APOL1OVEAGT_cells_follicular_helper4.5347e-050.2383image
chr22:36266068-36266899:+PAADEERMacrophages_M12.0562e-020.1735image
ENSG00000100342.19,APOL1PAADEAGMacrophages_M12.0562e-020.1735image
chr22:36266068-36266899:+PCPGEERT_cells_follicular_helper6.5340e-040.2604image
ENSG00000100342.19,APOL1PCPGEAGT_cells_follicular_helper6.5340e-040.2604image
chr22:36266068-36266899:+PRADEERT_cells_follicular_helper1.6678e-020.1083image
ENSG00000100342.19,APOL1PRADEAGT_cells_follicular_helper1.6154e-020.1088image
chr22:36266068-36266899:+SARCEERMast_cells_resting1.8445e-02-0.1505image
ENSG00000100342.19,APOL1SARCEAGMast_cells_resting1.8445e-02-0.1505image
chr22:36266068-36266899:+SKCMEERMacrophages_M07.6983e-03-0.1269image
ENSG00000100342.19,APOL1SKCMEAGMacrophages_M07.6983e-03-0.1269image
chr22:36266068-36266899:+STADEERDendritic_cells_activated3.4996e-060.2414image
ENSG00000100342.19,APOL1STADEAGDendritic_cells_activated3.5656e-060.2412image
chr22:36266068-36266899:+TGCTEERT_cells_CD4_naive2.6349e-030.2439image
ENSG00000100342.19,APOL1TGCTEAGT_cells_CD4_naive2.6349e-030.2439image
chr22:36266068-36266899:+THCAEERMonocytes1.2501e-030.1436image
ENSG00000100342.19,APOL1THCAEAGMonocytes1.2501e-030.1436image
chr22:36266068-36266899:+THYMEERMacrophages_M11.3561e-050.3888image
ENSG00000100342.19,APOL1THYMEAGMacrophages_M11.3561e-050.3888image
chr22:36266068-36266899:+UCECEERT_cells_CD4_memory_resting2.1043e-04-0.2814image
ENSG00000100342.19,APOL1UCECEAGT_cells_CD4_memory_resting2.1043e-04-0.2814image
chr22:36266068-36266899:+UVMEERMonocytes1.4207e-020.3802image
ENSG00000100342.19,APOL1UVMEAGMonocytes1.4207e-020.3802image


Top

6. Enriched editing regions and immune gene sets for APOL1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr22:36266068-36266899:+BLCAEER7.6076e-03image1.1386e-080.2789image
ENSG00000100342.19,APOL1BLCAEAG7.6076e-03image1.1386e-080.2789image
chr22:36266068-36266899:+KIRPEER1.0493e-02image4.2229e-040.2078image
ENSG00000100342.19,APOL1KIRPEAG1.0493e-02image4.2229e-040.2078image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr22:36266068-36266899:+BLCAEER8.3515e-140.35961.6797e-080.27587.1955e-100.30002.1044e-070.2544image
ENSG00000100342.19,APOL1BLCAEAG8.3514e-140.35961.6797e-080.27587.1954e-100.30002.1044e-070.2544image
chr22:36266068-36266899:+DLBCEER4.0230e-020.29721.9744e-020.33559.8365e-040.46074.6043e-030.4022image
ENSG00000100342.19,APOL1DLBCEAG4.0230e-020.29721.9744e-020.33559.8365e-040.46074.6043e-030.4022image
chr22:36266068-36266899:+HNSCEER1.0357e-050.19624.7728e-03-0.12634.7119e-060.20357.0972e-050.1771image
ENSG00000100342.19,APOL1HNSCEAG1.0357e-050.19624.7728e-03-0.12634.7119e-060.20357.0972e-050.1771image
chr22:36266068-36266899:+LUADEER5.8746e-110.28546.6933e-120.29867.2715e-100.26922.2617e-030.1353image
ENSG00000100342.19,APOL1LUADEAG5.8746e-110.28546.6933e-120.29867.2715e-100.26922.2617e-030.1353image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr22:36266068-36266899:+ACCGSVA_HALLMARK_PROTEIN_SECRETIONEER5.7374e-03-0.3416image
ENSG00000100342.19,APOL1ACCGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.7374e-03-0.3416image
chr22:36266068-36266899:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.9650e-160.3933image
ENSG00000100342.19,APOL1BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.9650e-160.3933image
ENSG00000100342.19,APOL1BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9372e-220.2920image
chr22:36266068-36266899:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9372e-220.2920image
ENSG00000100342.19,APOL1CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.6124e-090.3260image
chr22:36266068-36266899:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.6124e-090.3260image
chr22:36266068-36266899:+CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEER1.5511e-020.4060image
ENSG00000100342.19,APOL1CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5511e-020.4060image
chr22:36266068-36266899:+COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.2129e-070.3061image
ENSG00000100342.19,APOL1COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.2129e-070.3061image
chr22:36266068-36266899:+DLBCGSVA_HALLMARK_APOPTOSISEER1.9564e-040.5126image
ENSG00000100342.19,APOL1DLBCGSVA_HALLMARK_APOPTOSISEAG1.9564e-040.5126image
ENSG00000100342.19,APOL1ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.0344e-03-0.2329image
chr22:36266068-36266899:+ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.0276e-03-0.2330image
ENSG00000100342.19,APOL1GBMGSVA_HALLMARK_DNA_REPAIREAG4.5876e-020.1690image
chr22:36266068-36266899:+GBMGSVA_HALLMARK_DNA_REPAIREER4.5876e-020.1690image
ENSG00000100342.19,APOL1HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.3686e-260.4477image
chr22:36266068-36266899:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.3686e-260.4477image
ENSG00000100342.19,APOL1KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2337e-040.1944image
chr22:36266068-36266899:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2402e-040.1944image
ENSG00000100342.19,APOL1KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG9.1883e-070.2864image
chr22:36266068-36266899:+KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER9.1883e-070.2864image
ENSG00000100342.19,APOL1LGGGSVA_HALLMARK_COAGULATIONEAG4.1757e-06-0.2435image
chr22:36266068-36266899:+LGGGSVA_HALLMARK_COAGULATIONEER4.1757e-06-0.2435image
ENSG00000100342.19,APOL1LIHCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG2.5864e-06-0.2406image
chr22:36266068-36266899:+LIHCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.4084e-06-0.2414image
ENSG00000100342.19,APOL1LUADGSVA_HALLMARK_E2F_TARGETSEAG4.0997e-090.2574image
chr22:36266068-36266899:+LUADGSVA_HALLMARK_E2F_TARGETSEER4.0997e-090.2574image
ENSG00000100342.19,APOL1LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.9047e-090.2586image
chr22:36266068-36266899:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.9047e-090.2586image
ENSG00000100342.19,APOL1MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6490e-060.4922image
chr22:36266068-36266899:+MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6490e-060.4922image
chr22:36266068-36266899:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5233e-070.3038image
ENSG00000100342.19,APOL1OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5233e-070.3038image
ENSG00000100342.19,APOL1PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.4767e-03-0.2179image
chr22:36266068-36266899:+PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.4767e-03-0.2179image
ENSG00000100342.19,APOL1PRADGSVA_HALLMARK_APICAL_SURFACEEAG7.0474e-06-0.2018image
chr22:36266068-36266899:+PRADGSVA_HALLMARK_APICAL_SURFACEEER6.2554e-06-0.2029image
chr22:36266068-36266899:+READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.3252e-030.2998image
ENSG00000100342.19,APOL1READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.3252e-030.2998image
chr22:36266068-36266899:+SARCGSVA_HALLMARK_MYOGENESISEER1.1849e-03-0.2060image
ENSG00000100342.19,APOL1SARCGSVA_HALLMARK_MYOGENESISEAG1.1849e-03-0.2060image
ENSG00000100342.19,APOL1SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.2155e-020.1090image
chr22:36266068-36266899:+SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER2.2155e-020.1090image
ENSG00000100342.19,APOL1STADGSVA_HALLMARK_MTORC1_SIGNALINGEAG9.0185e-090.2967image
chr22:36266068-36266899:+STADGSVA_HALLMARK_MTORC1_SIGNALINGEER9.0537e-090.2967image
chr22:36266068-36266899:+TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEER9.6780e-030.2106image
ENSG00000100342.19,APOL1TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEAG9.6780e-030.2106image
chr22:36266068-36266899:+THCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.3863e-020.1098image
ENSG00000100342.19,APOL1THCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.3863e-020.1098image
chr22:36266068-36266899:+THYMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.4211e-060.4184image
ENSG00000100342.19,APOL1THYMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.4211e-060.4184image
chr22:36266068-36266899:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6914e-060.3439image
ENSG00000100342.19,APOL1UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.6914e-060.3439image
ENSG00000100342.19,APOL1UVMGSVA_HALLMARK_PROTEIN_SECRETIONEAG8.3750e-03-0.4064image
chr22:36266068-36266899:+UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER8.3750e-03-0.4064image


Top

7. Enriched editing regions and drugs for APOL1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000100342.19,APOL1ACCAG.014699EAG2.5918e-02-0.2784image
chr22:36266068-36266899:+ACCAG.014699EER2.5918e-02-0.2784image
ENSG00000100342.19,APOL1BLCACMKEAG9.1890e-15-0.3723image
chr22:36266068-36266899:+BLCACMKEER9.1890e-15-0.3723image
chr22:36266068-36266899:+BRCAImatinibEER2.9995e-130.2207image
ENSG00000100342.19,APOL1BRCAImatinibEAG2.9995e-130.2207image
ENSG00000100342.19,APOL1CESCAKT.inhibitor.VIIIEAG1.2164e-070.2987image
chr22:36266068-36266899:+CESCAKT.inhibitor.VIIIEER1.2164e-070.2987image
chr22:36266068-36266899:+CHOLAMG.706EER4.7033e-020.3380image
ENSG00000100342.19,APOL1CHOLAMG.706EAG4.7033e-020.3380image
chr22:36266068-36266899:+COADCHIR.99021EER3.5582e-050.2497image
ENSG00000100342.19,APOL1COADCHIR.99021EAG3.5582e-050.2497image
ENSG00000100342.19,APOL1DLBCBosutinibEAG2.9476e-050.5695image
chr22:36266068-36266899:+DLBCBosutinibEER2.9476e-050.5695image
ENSG00000100342.19,APOL1ESCABI.D1870EAG1.8068e-03-0.2448image
chr22:36266068-36266899:+ESCABI.D1870EER1.8031e-03-0.2449image
ENSG00000100342.19,APOL1GBMJNJ.26854165EAG2.6513e-030.2522image
chr22:36266068-36266899:+GBMJNJ.26854165EER2.6513e-030.2522image
ENSG00000100342.19,APOL1HNSCAZD6244EAG1.9682e-18-0.3794image
chr22:36266068-36266899:+HNSCAZD6244EER1.9682e-18-0.3794image
chr22:36266068-36266899:+KICHGDC.0449EER1.3424e-02-0.3052image
ENSG00000100342.19,APOL1KICHGDC.0449EAG1.3424e-02-0.3052image
chr22:36266068-36266899:+KIRCAS601245EER2.4050e-060.2377image
ENSG00000100342.19,APOL1KIRCAS601245EAG2.4846e-060.2374image
chr22:36266068-36266899:+KIRPCCT007093EER1.1441e-050.2571image
ENSG00000100342.19,APOL1KIRPCCT007093EAG1.1441e-050.2571image
ENSG00000100342.19,APOL1LAMLJNJ.26854165EAG1.2912e-020.3997image
chr22:36266068-36266899:+LGGKU.55933EER1.4371e-040.2024image
ENSG00000100342.19,APOL1LGGKU.55933EAG1.4371e-040.2024image
ENSG00000100342.19,APOL1LIHCLFM.A13EAG1.7920e-080.2864image
chr22:36266068-36266899:+LIHCLFM.A13EER1.9565e-080.2856image
ENSG00000100342.19,APOL1LUADCMKEAG6.3738e-07-0.2190image
chr22:36266068-36266899:+LUADCMKEER6.3738e-07-0.2190image
ENSG00000100342.19,APOL1LUSCGemcitabineEAG3.2672e-07-0.2267image
chr22:36266068-36266899:+LUSCGemcitabineEER3.2672e-07-0.2267image
ENSG00000100342.19,APOL1MESOJNK.Inhibitor.VIIIEAG9.3300e-04-0.3588image
chr22:36266068-36266899:+MESOJNK.Inhibitor.VIIIEER9.3300e-04-0.3588image
ENSG00000100342.19,APOL1OVCHIR.99021EAG3.2626e-030.1731image
chr22:36266068-36266899:+OVCHIR.99021EER3.2626e-030.1731image
ENSG00000100342.19,APOL1PAADCI.1040EAG3.8119e-04-0.2634image
chr22:36266068-36266899:+PAADCI.1040EER3.8119e-04-0.2634image
chr22:36266068-36266899:+PCPGDasatinibEER7.6624e-030.2088image
ENSG00000100342.19,APOL1PCPGDasatinibEAG7.6624e-030.2088image
ENSG00000100342.19,APOL1PRADAS601245EAG8.4685e-040.1506image
chr22:36266068-36266899:+PRADAS601245EER6.9265e-040.1531image
chr22:36266068-36266899:+READBIRB.0796EER4.9368e-020.2033image
ENSG00000100342.19,APOL1READBIRB.0796EAG4.9368e-020.2033image
chr22:36266068-36266899:+SARCMethotrexateEER2.5471e-05-0.2660image
ENSG00000100342.19,APOL1SARCMethotrexateEAG2.5471e-05-0.2660image
chr22:36266068-36266899:+SKCMDoxorubicinEER2.9398e-02-0.1038image
ENSG00000100342.19,APOL1SKCMDoxorubicinEAG2.9398e-02-0.1038image
ENSG00000100342.19,APOL1STADImatinibEAG8.3335e-050.2056image
chr22:36266068-36266899:+STADImatinibEER8.3119e-050.2056image
chr22:36266068-36266899:+TGCTCisplatinEER3.5338e-03-0.2368image
ENSG00000100342.19,APOL1TGCTCisplatinEAG3.5338e-03-0.2368image
ENSG00000100342.19,APOL1THCALapatinibEAG1.0809e-040.1719image
chr22:36266068-36266899:+THCALapatinibEER1.0809e-040.1719image
chr22:36266068-36266899:+THYMABT.263EER9.5669e-080.4673image
ENSG00000100342.19,APOL1THYMABT.263EAG9.5669e-080.4673image
ENSG00000100342.19,APOL1UCECABT.888EAG3.2129e-06-0.3494image
chr22:36266068-36266899:+UCECABT.888EER3.2129e-06-0.3494image
ENSG00000100342.19,APOL1UCSA.443654EAG1.9202e-020.3335image
chr22:36266068-36266899:+UCSA.443654EER1.9202e-020.3335image
ENSG00000100342.19,APOL1UVMAZD6244EAG1.8964e-02-0.3650image
chr22:36266068-36266899:+UVMAZD6244EER1.8964e-02-0.3650image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr22:36266068-36266899:+ENST00000397279.7O14791DB01593ZincSmallMoleculeDrug
chr22:36266068-36266899:+ENST00000397279.7O14791DB14487Zinc acetateSmallMoleculeDrug
chr22:36266068-36266899:+ENST00000397279.7O14791DB14533Zinc chlorideSmallMoleculeDrug